..
Progenitor Cell Therapy
21 Main Street
Court Plaza South, East Wing - Suite 304
Hackensack
New Jersey
07601
U.S.A.
Phone:
201-883-5300
Fax:
201-883-1406
|
|
Progenitor Cell Therapy's management team, extensive manufacturing and regulatory experience, and facilities have made it the industry's partner of choice for the development and manufacture of cell therapies.
Whether you are in the early stages of product development, in clinical trials, or moving to commercialization, PCT can provide you with the consultative or manufacturing partnership you need to get your product to market.
PCT is a client-based cell therapy services company that supports the development of cellular therapies by providing cGMP-compliant cell manufacturing and consulting services that address regulatory, financial, technical, process and quality systems needs.
The PCT advantage includes:
Focus and Commitment to Cell Therapies
PCT works with its clients at the bench or in the market to advance cell therapy products and the companies behind them.
Unparalleled Expertise
PCT’s management team has incomparable experience with cell-based therapeutics including 14,000+ cell therapy procedures, 10,000+ cellular products manufactured, and participation in more than 50 clinical trials in the US and Europe.
Sate-of-the-art cG(x)P Facilities
Fully licensed contract manufacturing facilities located on the East (Hackensack, NJ) and West (Mountain View, CA) coasts of the USA. Manufacturing is performed in ISO Class 7/Class 10,000 or ISO Class 8/ Class 100,000 clean rooms. Both facilities have onsite QA, fully equipped QC laboratories, controlled materials warehousing and fully equipped R&D laboratories.
Regulatory Leadership
PCT has years of experience in, and numerous successful examples of, working with US and international regulatory authorities.
National Coverage
It is critical to PCT’s business that we maintain an air and ground transportation network that provides 24/7 processing and delivery options.
Extensive Industry Network
No company has a broader base of internal and external content experts in the cell therapy sector than PCT. PCT’s clients, consultants, strategic partners, collaborators, and independent contracts represent the industry’s leaders in cell-based product development, research, and patient care.
PCT’s cGMP nationwide network of laboratories enables it to provide a full spectrum of support services, including:
assay development,
process development and/or validation,
product characterization and/or development,
product comparability studies,
product validations,
technology and/or licensing evaluation assessments,
facility planning,
financial modeling for product development and commercialization,
strategic development and/or project management
quality plan/protocols/systems audits,
product manufacturing for clinical trials,
commercial-scale product manufacturing,
Master File development,
IND applications,
CMC development,
Biological License Applications (BLA),
preparation for and/or representation at regulatory meetings,
regulatory submissions, amendments, supplements, and reports,
clinical research,
cell and tissue collection, processing, and/or storage
diagnostics/biologic product testing, and
product distribution and/or transportation.
Last updated: 06-09-2006
Email:
info@progenitorcelltherapy.com
Ownership:
Private
Web Site:
Progenitor Cell Therapy
Employees:
Symbol:
|
|
|
Company News |
NeoStem, Inc.'s Subsidiary, Progenitor Cell Therapy, Enters Into a Manufacturing Agreement With ImmunoCellular Therapeutics, Ltd. for Dendritic Cell Vaccines Targeting Brain and Other Cancers
6/3/2013 9:37:20 AM
More...
|
NeoStem, Inc.'s Subsidiary, Progenitor Cell Therapy, Enters Into a Services Agreement With Sentien Biotechnologies, Inc.
4/29/2013 11:31:02 AM
More...
|
Sistemic Ltd and Leading CDMO, Progenitor Cell Therapy Initiate Study on Novel Stem Cell Characterisation Technology
3/13/2013 9:54:01 AM
More...
|
NeoStem, Inc.'s Subsidiary, Progenitor Cell Therapy, Enters Into a Cell Therapy Manufacturing Services Agreement With Adaptimmune Ltd.
1/16/2013 9:18:02 AM
More...
|
NeoStem, Inc.'s Subsidiary, Progenitor Cell Therapy, and Hackensack University Medical Center Enter Into a Cell Processing and Storage Services Agreement
1/7/2013 9:42:17 AM
More...
|
Progenitor Cell Therapy, a NeoStem, Inc. Company, Invited to Present at Two Conferences in September
9/5/2012 9:34:04 AM
More...
|
NeoStem, Inc.'s Subsidiary, Progenitor Cell Therapy, and SOTIO Enter Into a Phase 3 Manufacturing Services Agreement
7/16/2012 9:34:58 AM
More...
|
Islet Sciences Signs Cell Therapy Alliance and Service Agreement With Progenitor Cell Therapy
1/12/2012 9:38:11 AM
More...
|
Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management
10/19/2011 11:23:02 AM
More...
|
NeoStem, Inc.'s Subsidiary, Progenitor Cell Therapy, and ImmunoCellular Therapeutics, Ltd Enter Into a Manufacturing Agreement
10/3/2011 12:30:02 PM
More...
|
|
|
|